Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. Articles
  3. cardiovascular event
Show results for
Products

Companies

News
Articles

Refine by
Date

  • Older

Cardiovascular Event Articles & Analysis: Older

8 articles found

Peptides for Osteoporosis Research

Peptides for Osteoporosis Research

Hormone therapy also carries potential risks, such as a possible increased risk of cardiovascular events, breast cancer, deep vein thrombosis, pulmonary embolism, and gallbladder disease.Drugs That Promote Bone Formation(1) Parathyroid HormoneParathyroid hormone (PTH) as a bone formation promoter can effectively promote bone reconstruction, increase bone density, ...

ByBOC Sciences


Will Metformin Be Replaced By SGLT-2 Inhibitors

Will Metformin Be Replaced By SGLT-2 Inhibitors

For patients with previous cardiovascular disease, the risk of myocardial infarction was also significantly reduced. 3. ...

ByHunan Huateng Pharmaceutical Co. Ltd.


Huateng Pharma Develops Intermediates of Semaglutide For TD2

Huateng Pharma Develops Intermediates of Semaglutide For TD2

In order to improve public health and reduce mortality, it is urgent to effectively manage blood glucose and improve the risk factors of cardiovascular diseases, but the current situation of diabetes management is not optimistic. Diabetes and cardiovascular diseases are the leading causes of death from chronic noncommunicable diseases in middle-aged and older ...

ByHunan Huateng Pharmaceutical Co. Ltd.


In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome

In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome

Purpose Dysregulations of key signaling pathways in metabolic syndrome are multifactorial, eventually leading to cardiovascular events. Hyperglycemia in conjunction with dyslipidemia induces insulin resistance and provokes release of proinflammatory cytokines resulting in chronic inflammation, accelerated lipid peroxidation with further development of ...

ByVeriSIM Life


Five Year Outcomes in Patients with End Stage Renal Disease Who Received a Bioengineered Human Acellular Vessel for Dialysis Access

Five Year Outcomes in Patients with End Stage Renal Disease Who Received a Bioengineered Human Acellular Vessel for Dialysis Access

However, synthetic grafts have higher infection and stenosis rates than AV fistulas.1e6 Loss of primary unassisted patency in ePTFE grafts occurs in up to 75% of patients by one year,6 and long term patency rates are approximately 27% at five years.7 Graft and fistula failure can force patients to rely on central venous catheters, which are associated with higher rates of infection, all cause ...

ByHumacyte, Inc.


LimFlow Percutaneous Deep Venous Arterialization

LimFlow Percutaneous Deep Venous Arterialization

In patients with DM and CKD, MAC is a powerful risk factor for cardiovascular events and death. Furthermore, MAC and an elevated ankle-brachial index, secondary to noncompressible ankle arteries as a result of MAC, are correlated with clinical symptoms of CLTI, such as foot ulcer, gangrene, and amputations.5 ARE SAD AND MAC TWO FACES OF THE SAME COIN? ...

ByLimFlow, Inc.


Cardiovascular Consequences of Acute Kidney Injury

Cardiovascular Consequences of Acute Kidney Injury

Annotations Acute kidney injury (AKI) is recognized as a potential risk factor for future cardiovascular events, especially heart failure. Up to 60% of patients with severe AKI who are admitted to an intensive care unit (ICU) die; the long-term risk of death associated with AKI is also increased. ...

ByEliaz Therapeutics


Abstract 9761: Novel Modulators of Low Density Lipoprotein Receptor Metabolism

Abstract 9761: Novel Modulators of Low Density Lipoprotein Receptor Metabolism

Abstract Intervention with drugs to reduce Low Density Lipoprotein-cholesterol (LDL-C) has proven to decrease the risk of subsequent cardiovascular events, including mortality. Our goal is to develop novel, small molecule, LDL-C lowering drugs by targeting the Low Density Lipoprotein Receptor (LDLR) degradation pathway, which is modulated by the protease ...

ByShifa Biomedical Corporation

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT